Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cyteir Therapeutics Inc (NQ: CYT )

2.480 -0.030 (-1.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 12, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 137,677
Open 2.540
Bid (Size) 2.000 (1)
Ask (Size) 2.560 (1)
Prev. Close 2.510
Today's Range 2.370 - 2.550
52wk Range 1.555 - 22.85
Shares Outstanding 71,281,616
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
From Cyteir Therapeutics
Via Business Wire

Performance

YTD
-76.40%
-76.40%
1 Month
-36.41%
-36.41%
3 Month
+31.91%
+31.91%
6 Month
-58.67%
-58.67%
1 Year
-88.55%
-88.55%

More News

Read More
CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
From Cyteir Therapeutics
Via Business Wire
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
Via Benzinga
Cyteir Therapeutics Reports First Quarter 2022 Financial Results and Operational Highlights
From Cyteir Therapeutics
Via Business Wire
79 Biggest Movers From Yesterday
Via Benzinga
Cyteir Therapeutics to Participate in the 2022 Bank of America Healthcare Conference
From Cyteir Therapeutics
Via Business Wire
83 Biggest Movers From Yesterday
Via Benzinga
Cyteir Therapeutics Names Krisztina Nemenyi as Senior Vice President of Regulatory Affairs and Quality
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Names Adam Veness General Counsel
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics to Host Virtual Research and Development (R&D) Day on April 26, 2022
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
From Cyteir Therapeutics
Via Business Wire
68 Biggest Movers From Yesterday
Via Benzinga
Earnings Scheduled For March 16, 2022
Via Benzinga
64 Biggest Movers From Yesterday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Cyteir Therapeutics Announces the Appointment of Stephen Sands to Board of Directors
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Announces First Patient Dosed in Phase 2 with CYT-0851
From Cyteir Therapeutics
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 7, 2022
Via Benzinga
Cyteir Therapeutics Announces the Appointment of John F. Thero to Board of Directors
From Cyteir Therapeutics
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
54 Biggest Movers From Yesterday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.